Kornimate/medical-research-clean huggingface dataset:
postoperative analgesia after video-assisted thoracoscopic surgery

Conditions: Postoperative Pain Management, After VATS

Summary: video-assisted thoracoscopic surgery (vats) is a commonly performed minimally invasive procedure that has lead to lower levels of pain. however, vats require analgesia that blocks both visceral and somatic nerve fibers for more effective pain control. in this study investigators will compare the analgesic effect of ultrasound guided erector spinae plane block (espb) and thoracic paravertebral block (tpvb) after vats.

all patients will be assessed preoperatively by careful history taking, full physical examination, laboratory evaluation and other appropriate investigations. at the preoperative visit, all patients will be instructed on how to evaluate their own pain by using a 10-cm visual analog pain scale (0= no pain, 10= maximum pain imaginable). the nerve block will be performed in the preoperative block area following standardized monitoring, including noninvasive blood pressure (bp), electrocardiogram (ecg), and pulse oximetry (po). oxygen 23 l/min was applied through the nasal cannula, and midazolam 0.025 mg/kg iv, will be given. all blocks will be performed by the same two experienced senior attending doctors in ultrasound-guided nerve blocks. patients will be randomly assigned into one of the following groups using computer generated codes and closed opaque sealed envelopes and patient and anesthesiologist who collect data will not know which type of block administered (as block will be done in holding area): group 1 (tpvb group): patients will receive tpvb. group 2 (espb group): patients will receive espb block. the patient will be placed in the lateral position. both blocks will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath . the blocks will be performed unilateral at the t5-t6 level of the spine using an in-plane approach. pre-operative chest ultrasound will be done by the anesthesiologist to detect complications after the blockade (hematoma in the puncture site by direct visualization and pneumothorax by barcode/stratosphere sign).

Eligibility criteria:
inclusion criteria: * age eligible \>20 - \<70 yrs. * sex eligible both sex. * patients with american society of anesthesiologists (asa) physical status 13 who will be scheduled for vats, with three trochar ports. the trochar ports will be made at the fifth and sixth to intercostal levels. the chest drain will be inserted before the skin closure at the seventh or eighth intercostal level. exclusion criteria: * ≤20 or ≥70 years old. * declining to give written informed consent. * history of allergy to the medications used in the study. * contraindication to regional anesthesia (including coagulopathy (platelet count ≤ 80,000, inr ≥ 1.5) and local infection). * hepatic impairment (inr ≥1.5, bilirubin ≥2, albumin ≤2). * renal dysfunction (gfr \<50ml/min). * psychiatric disorder. * pregnancy. * body mass index (bmi) ≥40 or ≤18 kg/m2. * vats procedure converted to open. * patient with history of thoracic spine surgery.

Keywords: postoperative pain management
acetazolamide and spironolactone to increase natriuresis in congestive heart failure

Conditions: Heart Failure

Summary: this study has two primary objectives: 1. to compare combination therapy with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics (standard of care) in patients with acute decompensated heart failure at high risk for diuretic resistance. 2. to demonstrate the safety and efficacy of upfront therapy with spironolactone in addition to loop diuretic therapy in patients with acute decompensated heart failure at high risk for diuretic resistance.


Eligibility criteria:
inclusion criteria: * older than 18 years and able to give informed consent * clinical diagnosis of acute decompensated heart failure within the previous 8 h * at least two clinical signs of congestion (edema, ascites, jugular venous distension, or pulmonary vascular congestion on chest radiography) * maintenance therapy with oral loop diuretics at a dose of at least 1 mg bumetanide (1 mg bumetanide = 40 mg furosemide = 20 mg torsemide) for at least 1 month before hospital admission * nt-probnp \>1000 ng/l * left ventricular ejection fraction \<50% * at least one out of three of the following criteria: * serum sodium \<136 mmol/l * serum urea/creatinine ratio \>50 (comparable to a bun/creatinine ratio \>25) * admission serum creatinine increased with \>0.3 mg/dl compared to previous value within 3 months before admission exclusion criteria: * history of cardiac transplantation and/or ventricular assist device * concurrent diagnosis of an acute coronary syndrome defined as typical chest pain and/or electrocardiographic changes in addition to a troponin rise \>99th percentile * mean arterial blood pressure \<65 mmhg, or systolic blood pressure \<90 mmhg at the moment of admission * use of intravenous inotropes, vasopressors or nitroprusside at any time point during the study * a baseline estimated glomerular filtration rate \<15 ml/min/1.73m² according to the chronic kidney disease epidemiology collaboration (ckd-epi) formula at the moment of inclusion * use of renal replacement therapy or ultrafiltration before study inclusion * treatment with acetazolamide within the previous month * treatment with ≥2 mg bumetanide or an equivalent dose during the index hospitalization before randomization * use of diuretics, vasopressin antagonists or mineralocorticoid receptor antagonist not specified by the protocol * exposure to nephrotoxic agents (i.e. contrast dye) anticipated within 3 days

Keywords: acetazolamide bumetanide cardio-renal syndrome diuretics heart failure natriuresis spironolactone
safety and efficacy of methylene blue combined with amodiaquine or artesunate for malaria treatment in children of burkina faso

Conditions: Malaria

Summary: the purpose of the study is to investigate the safety and efficacy profile of a new paediatric mb formulation combined with aq or as and compared to as-aq in young african children with uncomplicated falciparum malaria.


Eligibility criteria:
inclusion criteria: * 0.5-5 year (6-59 months) old children * uncomplicated malaria caused by p. falciparum * asexual parasites ≥ 2000/µ and ≤ 200000/µ * axillary temperature ≥ 37.5 celsius or a history of fever during last 24 hours * burkinabe nationality * informed consent exclusion criteria: * complicated or severe malaria * any apparent significant disease * anaemia (haematocrit \< 21%) * treated in the same trial before * modern antimalarial treatment prior to inclusion (last three days), except children having been treated with chloroquine
virtual hypertension management pilot

Conditions: Hypertension; Electronic Health Record; Digital Health

Summary: investigators are examining the quality improvement impact of providing patients with a an electronic health record-connected blood pressure cuff. investigators will give half of patients already eligible for hypertension management within a clinical pharmacist panel, the ability to upload their blood pressure data into stanford's electronic health record.


Eligibility criteria:
inclusion criteria: * hypertension as defined by clinical pharmacist usual care panel (2 or more readings of blood pressure \>140/90) exclusion criteria: * pregnancy * chronic kidney disease iii or iv * systolic heart failure with ejection fraction \<35% * current use of 3 or more anti-hypertension drugs
revisional bariatric surgery experience

Conditions: Bariatric Surgery; Revisional Bariatric Surgery; Obesity Associated Disorder

Summary: the aim of this study is to assess the indications for revisional bariatric surgery and short-term revisional surgical outcomes such as weight loss, bmi variation, % excessive weight loss and % excessive bmi loss .prospectively-collected patient data will retrospectively reviewed. patient demographics, body mass index (bmi), primary and revision surgery types, indications of revision, outcomes of revisional surgery and follow-up data for comorbidities will investigated.


Eligibility criteria:
inclusion criteria: * between 18 to 65 years old, * patients who undergo revisional bariatric surgery due to renewed weight gain, stenosis or alkaline reflux after primary bariatric surgery exclusion criteria: * eating disorders, * alcoholic * cancer
the evaluation studies of curative effect of fu-zheng-qu-zhuo oral liquid in treatment of ischemic nephropathy

Conditions: Atherosclerotic Renal Artery Stenosis

Summary: • background: since evidence show that renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis\[1\], the aim of our study was to confirm fu-zheng-qu-zhuo (fzqzc) oral liquid, a herbal medicine, combined with optimal medical therapy of internal medicine (omt), including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines,resulted in greater renal function protection in patients with atherosclerotic renal artery stenosis ( aras) compared with omt alone. methods : a randomized, placebo-controlled, single centre clinical design. sixty patients with diagnosed atherosclerotic renal artery stenosis and had chronic kidney disease stage 3 will be recruited, and will be randomized into two groups in a 1:1 ratio ( fzqz and placebo group, 30 respectively). fzqz oral liquid or placebo 20 ml every time, three times a day for different groups, meanwhile, all participants in both treatment groups received omt, 6 months therapeutic period. serum creatinine, estimated glomerular filtration rate(egfr), urine protein, and cardiovascular and renal events (a composite end point of death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement therapy) will be compared between the groups as the outcome.


Eligibility criteria:
inclusion criteria: 1. met the aras diagnosis: renal angiography or magnetic resonance angiography (mra) shows renal artery with unilateral or bilateral stenosis at least 50%，and with artery atheromatous plague; 2. meeting with the diagnostic criteria of the k/doqi chronic kidney disease （egfr\<90ml/min）：light or moderate damage to kidney function，scr\<265.2µmol/l(3.0mg/dl). exclusion criteria: 1. patients with renal artery stenosis which had been suspected or final diagnosed to be fibromuscular dysplasia or takayasu arteritis; 2. blood pressure did not meet the target (\<140/90mmhg) after combinedly taking more three kinds of antihypertensive agents with maximum dose; 3. poor control of blood sugar in patients with diabetes ( glycosylated hemoglobin 8.0% or higher in the recent month); 4. history of peptic ulcer，with gastrointestinal bleeding in the recent 6 months; 5. decompensated cirrhosis; 6. hematologic disease or bleeding tendency; 7. repeated episodes of pulmonary edema, congestive heart failure, acute myocardial infarction, cerebral infarction and cerebral hemorrhage in recent 3 months; 8. suffering from malignant tumor and predicting life span less than 1 year.

Keywords: atherosclerotic renal artery stenosis, herbal medicine
efficacy and safety of esomeprazole once daily for the treatment of gerd in neonatal patients

Conditions: GERD

Summary: the purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.


Eligibility criteria:
inclusion criteria: * full-term or gestational age \>/= 28 to 44 weeks * in-patient in neonatal intensive care unit, special care nursery, or equivalent * patient must be on a stable mode of feeding or with minimal variations for at least 2 days prior to randomization exclusion criteria: * patients with a need for resectional or reconstructive surgery of the gastrointestinal tract * patients with any condition that may require surgery during the course of the study * patients with acute respiratory distress within 72 hours prior to enrollment

Keywords: neonates infants gerd reflux
patients pregnant women with or without primary antiphospholipid antibody syndrome

Conditions: Preeclampsia; Immunologic Disease; Antiphospholipid Antibody Syndrome Primary; Pregnancy Complications; Pregnancy, High Risk; Rheumatic Diseases

Summary: the purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of pe in pregnancy in women with primary aps. to construct reference intervals of placental angiogenesis markers specific to women affected by primary aps in pregnancy by measuring the levels of sflt-1and plgf in serum maternal serum and their sflt-1/plgf ratio during the trimesters of gestation (i tm, ii tm and iii tm). for this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.


Eligibility criteria:
inclusion criteria: * group 1 1. pregnant patients between the ages of 18 and 45 years. 2. diagnosis of primary aps, according to international classification criteria. * group 2 1. pregnant patients between the ages of 18 and 45 years. 2. patients with at least one previous full-term pregnancy. 3. no diagnosis of aps, according to international classification criteria. exclusion criteria: * group 1 1. pma pregnancies. 2. known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 3. previous thrombotic event 4. chronic renal failure not related to ad 5. previous history of oncology * group 2 1. pregnancy by pma. 2. previous history of polyabortion and/or late pregnancy complications. 3. known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 4. previous thrombotic event 5. previous history of oncology
a protocol for the safety and tolerance of intravenous isophosphoramide mustard (ipm) in patients with advanced cancer

Conditions: Advanced Cancer

Summary: the study of safety of isophosphoramide mustard (ipm) in the treatment of advanced cancer.


Eligibility criteria:
inclusion criteria: * metastatic and /or unresectable disease state after previous standard chemotherapy
the jetstream (jet) post-market registry

Conditions: Peripheral Arterial Diseases

Summary: the scope of the jet registry to observe long term treatment effects of jetstream navitus on various lesions types/morphologies.

* to observe the treatment effects of the jetstream navitus system in long, occluded, diffuse, thrombotic or calcified lesions in peripheral arterial disease of the common femoral, superficial femoral, or popliteal arteries. * to assess and quantify vessel patency 1 year post atherectomy treatment.

Eligibility criteria:
inclusion criteria: * patient is ≥ 18 years of age. * the target de novo or restenotic percutaneous transluminal angioplasty (pta) lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries. * the reference vessel lumen (proximal to target lesion) is ≥ 4.0mm. * evidence of ≥ 70% stenosis or occlusion confirmed by angiography. * guidewire must cross lesion(s) within the true lumen, without a sub-intimal course before the patient is considered as entered into the study. * patient is an acceptable candidate for percutaneous intervention using the jetstream navitus system in accordance with its labeled indications and instructions for use. * lesion length ≥ 4cm. * patient has a rutherford category score of 1-3. * patient has signed approved informed consent. * patient is willing to comply with the follow-up evaluations at specified times. exclusion criteria: * patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent. * patient is unable to take appropriate anti-platelet therapy. * patient has no patent distal runoff vessels. * patient has critical limb ischemia (i.e., rutherford class 4-6) * limited vascular access that precludes safe advancement of the jetstream navitus system to the target lesion(s). * interventional treatment is intended for in-stent restenosis. * patient has target vessel with moderate or severe angulation (e.g., \>30 degrees) or tortuosity at the treatment segment. * patient has a history of coagulopathy or hypercoagulable bleeding disorder. * patient is receiving hemodialysis or has significantly impaired renal function (creatinine is \> 2.5 mg/dl) at the time of treatment. * patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months. * patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days. * patient has had surgical or endovascular procedure in the same vascular territory within 30 days prior to the index procedure. * patient has any planned surgical intervention or endovascular procedure within 30 days after the index procedure. * use of another debulking device during the index procedure prior to the jetstream navitus system will exclude the patient.

Keywords: pad peripheral artery disease atherectomy
ropeginterferon alfa-2b in patients with polycythemia vera (pv) without symptomatic splenomegaly

Conditions: Polycythemia Vera

Summary: the primary objective of this non interventional study is to evaluate symptom burden in adult patients with pv without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. further patient-relevant endpoints include effectiveness including complete hematologic response (chr), event-free survival (efs), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.


Eligibility criteria:
inclusion criteria: * age ≥18 years * confirmed diagnosis of pv without symptomatic splenomegaly * indication and decision for treatment with ropeginterferon alfa-2b in accordance with current smpc * no prior treatment with ropeginterferon alfa-2b (patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.) * dated signature of informed consent form * participation in patient-reported outcome (pro) assessment in german language and completion of questionnaire at time of study enrollment * other criteria according to current summary of product characteristics exclusion criteria: * participation in an interventional clinical trial (except follow-up) * other contraindications according to current summary of product characteristics

Keywords: ropeginterferon alfa-2b polycythemia vera symptom burden myeloproliferative neoplasm
assesment of a predictive model dosage of epo in hemodialysis patients

Conditions: Anemia

Summary: assesment of a predictive model of anemia management: dosage of erythropoietin (epo) and iron adminsitration in hemodialysis patients.

anemia in patients on hemodialysis (hd ) is common and although usually responds well to treatment with erythropoiesis stimulating agents (esas ) , this dosage , based on different clinical protocols , often ignores the high variability inter- and intra -individual in patient response . the result leads to swings in the objective by different dosage range that is associated with multiple risks and side effects. there are artificial intelligence-based optimization methods that predict treatment with esas in maintaining patient hemoglobin target range . so far the model has been validated for the long half-life of epo ( darbepoetin ) with promising results. hypothesis: maintaining patients in hb levels esas range using short half-life , avoid the one hand , the need for transfusions and, secondly , the levels exceeding the upper range ( overshooting ), preventing the onset of a increased cardiovascular risk events. relevance:the results allow us to validate the model with short half-life esas optimizing the management of anemia and improving comorbidity associated with overdosage. summary: prospective observational study of paired data. data obtained from the data base euclid . data will be collected by clinical teams according to standard clinical practice. informed at the time of admission to the clinic consent will be obtained . all patient data including to november 15th 2014 and who have completed the study period to 30 april 2015. the results will be compared with those prior to the patient's inclusion in the study were processed. to detect a difference of 10% in the percentage of patients in the hemoglobin target range after intervention (from 70% to 80%) we will need a minimum sample size of 268 patients assuming an alpha error of 0.05, a beta error of 0.2 and a correlation between both observations of 0.1.

Eligibility criteria:
inclusion criteria: * \> 18 years * \> 3 months on hd / olhdf * treated with esas( epobeta ) from\> 3 months exclusion criteria: * chronic inflammatory diseases * liver cirrhosis * active neoplasms * immunosuppression or other antiinflammatory medication * patients who do not require treatment with esas

Keywords: hemodialyisis predictive model esas patients
study of bcma car-t in multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to infusion bcma car-t cells to the patients with relapsed and refractory multiple myeloma(mm), to assess the safety and feasibility of this strategy. the car enables the t cell to recognize and kill the mm cells through the recognition of bcma, a protein expressed of the surface of the malignant plasma cells in mm patients.


Eligibility criteria:
inclusion criteria: * 1. 18 years to 70 years, expected survival \> 3 months; * 2. confirmed diagnosis of active mm as defined by imwg. bcma expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry. * 3. bcma-expressing b cell malignancy must be assured and must be relapsed or refractory disease.； * 4. ecog performance status of 0-2; * 5. cardiac function: 1-2 levels; liver: tbil≤3uln，ast ≤2.5uln，alt ≤2.5uln; kidney: cr≤1.25uln; * 6. no serious allergic constitution; * 7. no other serous diseases that conflicts with the clinical program; * 8. no other cancer history; * 9. female participants of reproductive potential must have a negative serum pregnancy test; * 10. subjects must have signed written, informed consent. exclusion criteria: * 1. pregnant or lactating women; * 2. uncontrolled active infection, hiv infection, syphilis serology reaction positive; * 3. active hepatitis b or hepatitis c infection; * 4. recent or current use of glucocorticoid or other immunosuppressor; * 5. serious mental disorder; * 6. with severe cardiac, liver, renal insufficiency, diabetes and other diseases; * 7. participate in other clinical research in the past three months; previously treatment with any gene therapy products;